ContractopenCA
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
National Institutes of HealthDescription
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. Recipient: REVAGENIX INC Award Amount: $26.94M
Requirements
Source: USASpending.gov
Interested in this contract?
Sign up to get match scores, track opportunities, and manage proposals with AI-powered tools.
Contract Details
Value Range
Up to $26,940,000
Deadline
August 31, 2026
Geographic Scope
CA
Status
open
External Links
View Original ListingSee how well this contract matches your organization.
Get Your Match Score